250 related articles for article (PubMed ID: 11375248)
1. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
Mousa SA; Bozarth JM; Naik UP; Slee A
Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
[TBL] [Abstract][Full Text] [Related]
2. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
Mousa SA; Bozarth JM; Lorelli W; Forsythe MS; Thoolen MJ; Slee AM; Reilly TM; Friedman PA
J Pharmacol Exp Ther; 1998 Sep; 286(3):1277-84. PubMed ID: 9732389
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
Mousa SA; Khurana S; Forsythe MS
Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
[TBL] [Abstract][Full Text] [Related]
4. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
Hantgan RR; Stahle MC; Connor JH; Connor RF; Mousa SA
J Thromb Haemost; 2007 Mar; 5(3):542-50. PubMed ID: 17166246
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
[TBL] [Abstract][Full Text] [Related]
6. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
Billheimer JT; He B; Spitz SM; Stern AM; Seiffert D
Thromb Res; 2002 Sep; 107(6):303-17. PubMed ID: 12565717
[TBL] [Abstract][Full Text] [Related]
7. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
Mousa SA; Bozarth JM; Forsythe MS; Slee A
Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
[TBL] [Abstract][Full Text] [Related]
8. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
9. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
[TBL] [Abstract][Full Text] [Related]
10. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Mousa SA; Kapil R; Mu DX
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2535-41. PubMed ID: 10521384
[TBL] [Abstract][Full Text] [Related]
11. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
Mousa SA
Blood Coagul Fibrinolysis; 2007 Jan; 18(1):55-60. PubMed ID: 17179828
[TBL] [Abstract][Full Text] [Related]
12. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation.
Savi P; Zamboni G; Rescanières O; Herbert JM
Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography.
Mousa SA; Forsythe MS
Thromb Res; 2001 Oct; 104(1):49-56. PubMed ID: 11583738
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor.
Mutlib AE; Diamond S; Shockcor J; Way R; Nemeth G; Gan L; Christ DD
Xenobiotica; 2000 Nov; 30(11):1091-110. PubMed ID: 11197070
[TBL] [Abstract][Full Text] [Related]
16. Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia.
Mousa SA; Ahmad S
Am J Hematol; 2007 Apr; 82(4):276-82. PubMed ID: 17039513
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ; Sy SK; Ebling W; Fossler MJ; Cain VA; Mondick JT; Ma S; Kornhauser DM
J Clin Pharmacol; 2002 Jul; 42(7):738-53. PubMed ID: 12092741
[TBL] [Abstract][Full Text] [Related]
18. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
[TBL] [Abstract][Full Text] [Related]
19. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
[TBL] [Abstract][Full Text] [Related]
20. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
Mousa SA; Bozarth JM; Seiffert D; Feuerstein GZ
Blood Coagul Fibrinolysis; 2005 Apr; 16(3):165-71. PubMed ID: 15795533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
